Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.047
Buy
RSI(14)
56.543
Neutral
STOCH(KDJ)(9,3,3)
55.938
Sell
ATR(14)
0.113
Low Volatility
CCI(14)
109.223
Buy
Williams %R
42.308
Buy
TRIX(12,20)
1.543
Buy
StochRSI(14)
17.739
Sell
Search
Humacyte Inc
HUMAAdd to Watchlist
0.925USD
-0.075-7.51%
Market hours （ET）Quotes delayed by 15 min
205.35MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Humacyte Inc
Currency: USD Updated: 2026-05-14Key Insights
Humacyte Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 140 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.14.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Humacyte Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Humacyte Inc Highlights
StrengthsRisks
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.04M.
Overvalued
The company’s latest PE is -1.55, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.10M shares, decreasing 3.18% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 140.91K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.15.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
5.143
Target Price
+355.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-14The current financial score of Humacyte Inc is 6.06, ranking 288 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 495.00K, representing a year-over-year decrease of 4.26%, while its net profit experienced a year-over-year decrease of 145.02%.
Score
Financials
4.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.11
Operational Efficiency
2.88
Growth Potential
7.40
Shareholder Returns
7.13
Humacyte Inc's Company Valuation
Currency: USD Updated: 2026-05-14The current valuation score of Humacyte Inc is 6.68, ranking 226 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.55, which is 0.00% below the recent high of -1.55 and -1705.04% above the recent low of -27.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 140/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-14The current earnings forecast score of Humacyte Inc is 8.00, ranking 159 out of 382 in the Biotechnology & Medical Research industry. The average price target is 3.50, with a high of 25.00 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
5.143
Target Price
+355.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Humacyte Inc
HUMA
7
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Beigene Ltd
ONC
25
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-14The current price momentum score of Humacyte Inc is 6.99, ranking 153 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.26 and the support level at 0.70, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.020
Sell
MA10
0.985
Sell
MA20
0.867
Buy
MA50
0.854
Buy
MA100
0.964
Sell
MA200
1.278
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-14The current institutional shareholding score of Humacyte Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 32.47%, representing a quarter-over-quarter increase of 29.83%. The largest institutional shareholder is Invesco, holding a total of 140.91K shares, representing 0.06% of shares outstanding, with 1714.29% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-14The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Humacyte Inc is 3.56, ranking 130 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 2.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Humacyte Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
2.35
VaR
+8.61%
240-Day Maximum Drawdown
+78.96%
240-Day Volatility
+103.97%
Return
Best Daily Return
60 days
+24.18%
120 days
+30.02%
5 years
+34.10%
Worst Daily Return
60 days
-19.42%
120 days
-19.42%
5 years
-33.67%
Sharpe Ratio
60 days
+0.14
120 days
+0.20
5 years
-0.02
Risk Assessment
Maximum Drawdown
240 days
+78.96%
3 years
+93.93%
5 years
+96.62%
Return-to-Drawdown Ratio
240 days
-0.79
3 years
-0.23
5 years
-0.19
Skewness
240 days
+0.06
3 years
+0.43
5 years
+0.45
Volatility
Realised Volatility
240 days
+103.97%
5 years
+103.29%
Standardised True Range
240 days
+13.21%
5 years
+35.90%
Downside Risk-Adjusted Return
120 days
+37.62%
240 days
+37.62%
Maximum Daily Upside Volatility
60 days
+91.26%
Maximum Daily Downside Volatility
60 days
+82.65%
Liquidity
Average Turnover Rate
60 days
+4.42%
120 days
+3.89%
5 years
--
Turnover Deviation
20 days
+14.70%
60 days
+34.96%
120 days
+18.78%
Peer Comparison
Biotechnology & Medical Research
Humacyte Inc
HUMA
6.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.49 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
